Credit Suisse’s PAVmed PAVM Stock Holding History

Credit Suisse’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-136	Closed	-$393K	–	4507
2021 Q2	$393K	Buy	136 +106	+353%	+$250K	﹤0.01%	3983
2021 Q1	$59K	Buy	30 +6	+25%	+$9.02K	﹤0.01%	4220
2020 Q4	$23K	Buy	+24	New	+$20.5K	﹤0.01%	4300

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Credit Suisse's PAVM Position: Q3 2021 in Review

Credit Suisse sold out of PAVmed (PAVM) in Q3 2021, closing a stake of 136 shares — an estimated $393K sold.

Credit Suisse first reported a position in PAVM in Q4 2020 and held it in 3 quarters. The position peaked at $393K in Q2 2021. 107 funds tracked by Wall St. Rank hold PAVM as of Q3 2021.

Credit Suisse reported no remaining PAVmed position as of Q3 2021 after selling out during the quarter.
Credit Suisse sold 136 PAVmed shares in Q3 2021, an estimated $393K.
Credit Suisse first reported a position in PAVmed in Q4 2020 and held it in 3 quarters.
Credit Suisse's PAVmed position peaked at $393K in Q2 2021.
107 funds tracked by Wall St. Rank held PAVmed as of Q3 2021.

Based on Credit Suisse's 13F filing for Q3 2021, filed 12 Nov 2021.